H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016

  • ID: 3759011
  • Report
  • 208 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akshaya Bio Inc.
  • CEL-SCI Corporation
  • iBio, Inc.
  • MedImmune, LLC
  • OPKO Health, Inc.
  • TechnoVax, Inc.
  • MORE
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016

Summary

‘H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016’, provides an overview of the H5N1 Infection (Avian Influenza) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for H5N1 Infection (Avian Influenza), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H5N1 Infection (Avian Influenza) and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza)
- The report reviews pipeline therapeutics for H5N1 Infection (Avian Influenza) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved H5N1 Infection (Avian Influenza) therapeutics and enlists all their major and minor projects
- The report assesses H5N1 Infection (Avian Influenza) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for H5N1 Infection (Avian Influenza)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akshaya Bio Inc.
  • CEL-SCI Corporation
  • iBio, Inc.
  • MedImmune, LLC
  • OPKO Health, Inc.
  • TechnoVax, Inc.
  • MORE
Introduction

H5N1 Infection (Avian Influenza) Overview

Therapeutics Development

H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies

H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes

H5N1 Infection (Avian Influenza) - Pipeline Products Glance

H5N1 Infection (Avian Influenza) - Products under Development by Companies

H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes

H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development

H5N1 Infection (Avian Influenza) - Therapeutics Assessment

Drug Profiles

H5N1 Infection (Avian Influenza) - Recent Pipeline Updates

H5N1 Infection (Avian Influenza) - Dormant Projects

H5N1 Infection (Avian Influenza) - Discontinued Products

H5N1 Infection (Avian Influenza) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for H5N1 Infection (Avian Influenza), H1 2016

Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Akshaya Bio Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Altimmune, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Antigen Express, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Aphios Corporation, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by BioDiem Ltd, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by BiondVax Pharmaceuticals Ltd., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by CEL-SCI Corporation, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Cocrystal Pharma, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by CSL Limited, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Emergent BioSolutions Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Gemmus Pharma Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by GlaxoSmithKline Plc, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Hemispherx Biopharma, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by iBio, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Immunovaccine, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Johnson & Johnson, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Kineta, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Medicago Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by MedImmune, LLC, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Microbiotix, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by NanoBio Corporation, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Nanotherapeutics, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by NanoViricides, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by NewLink Genetics Corporation, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by OPKO Health, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by PaxVax, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by PeptiDream Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Protein Sciences Corporation, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Shionogi & Co., Ltd., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Sirnaomics, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by TechnoVax, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by TGV-Laboratories, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Theraclone Sciences, Inc., H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by Vaxine Pty Ltd, H1 2016

H5N1 Infection (Avian Influenza) - Pipeline by VaxInnate Corporation, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

H5N1 Infection (Avian Influenza) Therapeutics - Recent Pipeline Updates, H1 2016

H5N1 Infection (Avian Influenza) - Dormant Projects, H1 2016

H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..1), H1 2016

H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..2), H1 2016

H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..3), H1 2016

H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..4), H1 2016

H5N1 Infection (Avian Influenza) - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for H5N1 Infection (Avian Influenza), H1 2016

Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Akshaya Bio Inc.
Altimmune, Inc.
Antigen Express, Inc.
Aphios Corporation
BioDiem Ltd
BiondVax Pharmaceuticals Ltd.
CEL-SCI Corporation
Cocrystal Pharma, Inc.
CSL Limited
Daiichi Sankyo Company, Limited
Emergent BioSolutions Inc.
Gemmus Pharma Inc.
GlaxoSmithKline Plc
Hemispherx Biopharma, Inc.
iBio, Inc.
Immunovaccine, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Kineta, Inc.
Medicago Inc.
MedImmune, LLC
Microbiotix, Inc.
NanoBio Corporation
Nanotherapeutics, Inc.
NanoViricides, Inc.
NewLink Genetics Corporation
OPKO Health, Inc.
PaxVax, Inc.
PeptiDream Inc.
Protein Sciences Corporation
Shionogi & Co., Ltd.
Sirnaomics, Inc.
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
TGV-Laboratories
Theraclone Sciences, Inc.
Vaxine Pty Ltd
VaxInnate Corporation
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll